Rather than stopping entirely and risking the weight regain documented in the STEP 1 extension trial (Wilding et al., Diabetes Obes Metab, 2022), where participants regained two-thirds of lost weight within one year of stopping, a microdose may provide enough GLP-1 receptor activation to maintain the appetite set-point shift
In the STEP trials (the largest real-world semaglutide studies), participants averaged 1015% body weight loss over 68 weeks, with significant reductions in waist circumference and visceral fat imaging
No upsell
Athletes should not rely on influencer advice, vendor claims, or gym-based protocols to determine whether a substance is permitted
The SOUL trial included 9650 participants (randomized 1:1 to oral semaglutide or placebo), of whom 2596 (26.9%) were using SGLT2i at baseline and 4718 (48.9%) had any SGLT2i use during the trial
Your doctor submits a flawless prior authorization, and after weeks of waiting, you get the approval